fluorobenzenes has been researched along with Acute Coronary Syndrome in 44 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (15.91) | 29.6817 |
| 2010's | 37 (84.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aggarwal, RK; Showkathali, R | 1 |
| Gong, HR; Huang, WY; Huang, XS; Li, XP; Zhao, SP | 1 |
| Roberts, A | 1 |
| Briguori, C; Marenzi, G | 1 |
| Bellandi, F; Colonna, G; Di Sciascio, G; Grieco, D; Leoncini, M; Maioli, M; Patti, G; Toso, A | 1 |
| Garg, AX; Molnar, AO | 1 |
| Alessi, MC; Bonnet, G; Bonnet, JL; Cuisset, T; Deharo, P; Grosdidier, C; Morange, P; Pankert, M; Quilici, J; Verdier, V | 1 |
| Jiang, F; Li, R; Sun, L; Yang, J; Zhang, L; Zhao, Q; Zhuo, L | 1 |
| Cao, F; Chen, Y; Gao, H; Liang, D; Wang, J; Yan, W; Yang, H; Zhang, Q; Zhang, R; Zhang, X | 1 |
| Ballantyne, CM; Barter, PJ; Chapman, MJ; Erbel, R; Kataoka, Y; Libby, P; Nicholls, SJ; Nissen, SE; Puri, R; Raichlen, JS; Shao, M; Uno, K | 1 |
| Chen, J; Li, P; Liang, X; Lin, Z; Mo, Y; Wang, Z; Xie, W | 1 |
| Ball, T; McCullough, PA | 1 |
| Berdan, LG; Bessac, L; Bhatt, DL; Bittner, V; Diaz, R; Goodman, SG; Hanotin, C; Harrington, RA; Jukema, JW; Mahaffey, KW; Moryusef, A; Pordy, R; Roe, MT; Rorick, T; Sasiela, WJ; Schwartz, GG; Shirodaria, C; Steg, PG; Szarek, M; Tamby, JF; Tricoci, P; White, H; Zeiher, A | 1 |
| Badia, T; Bellandi, F; Leoncini, M; Maioli, M; Toso, A; Tropeano, F; Villani, S | 1 |
| Bellandi, F; Di Vincenzo, E; Leoncini, M; Maioli, M; Toso, A; Tropeano, F; Villani, S | 1 |
| Bailey, AL; Campbell, CL; Charnigo, RJ; Evangelista, V; Macaulay, TE; Sexton, TR; Smyth, SS; Wallace, EL | 1 |
| Abaci, O; Arat Ozkan, A; Baydar, O; Cetinkal, G; Gurmen, T; Kaya, A; Kocas, C; Sukru Karaca, O | 1 |
| Fujiwara, W; Hayashi, M; Ito, T; Izawa, H; Kamada, T; Mukaide, D; Ozaki, Y; Sugishita, Y; Yokoi, H; Yoshikawa, D; Yoshinaga, M | 1 |
| Hammer, HB; Hisdal, J; Holme, I; Ikdahl, E; Kitas, GD; Kvien, TK; Olsen, IC; Pedersen, TR; Rollefstad, S; Semb, AG; Smerud, KT | 1 |
| E Madias, J | 1 |
| Ahn, YK; Jeong, JW; Jeong, MH; Kim, NH; Lee, EM; Oh, SK; Park, EM; Rhee, SJ; Yoo, NJ; Yun, KH | 1 |
| Boccara, F; Hatem, S | 1 |
| Alonso, J; Crean, P; Danchin, N; Farah, M; Farnier, M; Lablanche, JM; Leone, A; Licour, M; Morais, J; Santini, M; Tardif, JC; Tedgui, A; Vicaut, E | 1 |
| Gratsianskiĭ, NA; Kuznetsova, MA; Masenko, VP; Vaulin, NA | 1 |
| Alonso, J; Demil, N; Eha, J; Lablanche, JM; Leone, A; Licour, M; Merkely, B; Morais, J; Santini, M; Tardif, JC | 1 |
| Jeong, JW; Kim, NH; Oh, SK; Rhee, SJ; Yoo, NJ; Yun, KH | 1 |
| Abel, T; Fehér, J | 1 |
| Alessi, MC; Bonnet, JL; Camoin, L; Cuisset, T; Frere, C; Gaborit, B; Morange, PE; Moro, PJ; Poyet, R; Quilici, J | 1 |
| Böhm, M; Hewera, L; Link, A; Nickenig, G; Selejan, S; Walter, F | 1 |
| Cay, S | 1 |
| Aizawa, K; Ikeda, U; Izawa, A; Kasai, H; Koshikawa, M; Koyama, J; Kumazaki, S; Miyashita, Y; Otagiri, K; Tomita, T; Tsutsui, H | 1 |
| Horii, M; Ishigami, K; Kawakami, R; Kawata, H; Matsumoto, T; Nakagawa, H; Nishida, T; Okayama, S; Saito, Y; Senoo, A; Soeda, T; Somekawa, S; Sugawara, Y; Sung, JH; Takeda, Y; Uemura, S | 1 |
| Loscalzo, J; Miller, E; Monyak, J; Pitt, B; Raichlen, J | 1 |
| Spiegel, R | 1 |
| Chang, K; Gwon, HC; Jeon, DS; Kim, HS; Kim, MJ; Kim, SJ; Tahk, SJ | 1 |
| Gao, Y; Jia, ZM; Qi, GX; Ren, LN; Sun, YJ; Zhang, ZH | 1 |
| Jeong, JW; Kim, NH; Ko, JS; Oh, SK; Rhee, SJ; Shin, SN; Yun, KH | 1 |
| Fang, Z; Hu, X; Li, J; Luo, J; Lv, X; Shen, X; Zhou, S | 1 |
| Ballantyne, CM; Cain, VA; Loscalzo, J; Pitt, B; Raichlen, JS | 1 |
| Dai, H; Ge, Z; Hou, F; Lin, X; Ma, Y; Ren, Y; Tan, K; Wang, S; Wang, Y; Wang, Z; Xing, M; Yu, Z; Zhang, J | 1 |
| Cannon, CP; Kumar, A | 1 |
| García-Moll, X | 1 |
| Miller, M | 1 |
| Loscalzo, J; Pitt, B; Raichlen, JS; Ycas, J | 1 |
4 review(s) available for fluorobenzenes and Acute Coronary Syndrome
| Article | Year |
|---|---|
Rosuvastatin calcium in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Animals; Cholesterol, LDL; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Practice Guidelines as Topic; Pyrimidines; Rosuvastatin Calcium; Secondary Prevention; Sulfonamides | 2013 |
Statins for the prevention of contrast-induced acute kidney injury.
Topics: Acute Coronary Syndrome; Acute Kidney Injury; Albuminuria; Contrast Media; Coronary Angiography; Creatinine; Diabetes Complications; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inactivation, Metabolic; Kidney Tubules; Lipoproteins; Meta-Analysis as Topic; Muscle Cells; Percutaneous Coronary Intervention; Pyrimidines; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Renal Replacement Therapy; Rhabdomyolysis; Rosuvastatin Calcium; Sulfonamides | 2014 |
[Role of rosuvastatin in current lipid-lowering therapy].
Topics: Acute Coronary Syndrome; Atherosclerosis; C-Reactive Protein; Cholesterol; Disease Progression; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Meta-Analysis as Topic; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2010 |
Importance of intensive lipid lowering in acute coronary syndrome and percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Angiography; Coronary Disease; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Ultrasonography, Interventional | 2007 |
25 trial(s) available for fluorobenzenes and Acute Coronary Syndrome
| Article | Year |
|---|---|
The influence of statin-fibrate combination therapy on lipids profile and apolipoprotein A5 in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Apolipoprotein A-V; Apolipoproteins A; Atorvastatin; Bezafibrate; Cholesterol, HDL; Drug Synergism; Drug Therapy, Combination; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2013 |
Safety and effectiveness of the association ezetimibe-statin (E-S) versus high dose rosuvastatin after acute coronary syndrome: the SAFE-ES study.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2014 |
Rosuvastatin reduces ischemia-reperfusion injury in patients with acute coronary syndrome treated with percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Biomarkers; China; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Malondialdehyde; Middle Aged; Myocardial Reperfusion Injury; Natriuretic Peptide, Brain; Percutaneous Coronary Intervention; Pyrimidines; Rosuvastatin Calcium; Stroke Volume; Sulfonamides; Superoxide Dismutase; Time Factors; Treatment Outcome; Ventricular Function, Left | 2014 |
Anti-oxidative stress effect of loading-dose rosuvastatin prior to percutaneous coronary intervention in patients with acute coronary syndrome: a prospective randomized controlled clinical trial.
Topics: Acute Coronary Syndrome; Administration, Oral; Creatine Kinase, MB Form; Drug Administration Schedule; Female; Fluorobenzenes; Humans; Male; Middle Aged; Oxidative Stress; Percutaneous Coronary Intervention; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Troponin I | 2014 |
Antiatherosclerotic effects of long-term maximally intensive statin therapy after acute coronary syndrome: insights from Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Apolipoproteins A; Apolipoproteins B; Atorvastatin; Cholesterol, HDL; Coronary Artery Disease; Coronary Vessels; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Incidence; Longitudinal Studies; Male; Middle Aged; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Ultrasonography | 2014 |
Rosuvastatin may reduce the incidence of cardiovascular events in patients with acute coronary syndromes receiving percutaneous coronary intervention by suppressing miR-155/SHIP-1 signaling pathway.
Topics: Acute Coronary Syndrome; Aged; Cardiovascular Diseases; Cytokines; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inositol Polyphosphate 5-Phosphatases; Male; MicroRNAs; Middle Aged; Percutaneous Coronary Intervention; Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases; Phosphoric Monoester Hydrolases; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Signal Transduction; Sulfonamides; T-Lymphocytes, Regulatory | 2014 |
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.
Topics: Acute Coronary Syndrome; Angina, Unstable; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Fluorobenzenes; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Myocardial Infarction; Proprotein Convertase 9; Proprotein Convertases; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Serine Endopeptidases; Stroke; Sulfonamides; Treatment Outcome | 2014 |
Early high-dose rosuvastatin and cardioprotection in the protective effect of rosuvastatin and antiplatelet therapy on contrast-induced acute kidney injury and myocardial damage in patients with acute coronary syndrome (PRATO-ACS) study.
Topics: Acute Coronary Syndrome; Acute Kidney Injury; Cardiotonic Agents; Clopidogrel; Contrast Media; Coronary Angiography; Creatine Kinase, MB Form; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardium; Necrosis; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Ticlopidine; Treatment Outcome; Troponin I | 2014 |
Relationship between inflammation and benefits of early high-dose rosuvastatin on contrast-induced nephropathy in patients with acute coronary syndrome: the pathophysiological link in the PRATO-ACS study (Protective Effect of Rosuvastatin and Antiplatelet
Topics: Acute Coronary Syndrome; Acute Kidney Injury; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Biomarkers; C-Reactive Protein; Chi-Square Distribution; Contrast Media; Coronary Angiography; Creatinine; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Platelet Aggregation Inhibitors; Protective Factors; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome | 2014 |
The effect of rosuvastatin on platelet-leukocyte interactions in the setting of acute coronary syndrome.
Topics: Acute Coronary Syndrome; Blood Platelets; Cell Aggregation; Dose-Response Relationship, Drug; Double-Blind Method; Flow Cytometry; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocytes; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2015 |
Impact of Rosuvastatin on contrast-induced acute kidney injury in patients at high risk for nephropathy undergoing elective angiography.
Topics: Acute Coronary Syndrome; Acute Kidney Injury; Aged; Contrast Media; Coronary Angiography; Female; Fluorobenzenes; Follow-Up Studies; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Prognosis; Pyrimidines; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2015 |
Rosuvastatin-Induced Carotid Plaque Regression in Patients With Inflammatory Joint Diseases: The Rosuvastatin in Rheumatoid Arthritis, Ankylosing Spondylitis and Other Inflammatory Joint Diseases Study.
Topics: Acute Coronary Syndrome; Aged; Arthritis, Psoriatic; Arthritis, Rheumatoid; Carotid Stenosis; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Male; Middle Aged; Prospective Studies; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Spondylitis, Ankylosing; Sulfonamides; Treatment Outcome; Ultrasonography, Interventional | 2015 |
The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Biomarkers; Combined Modality Therapy; Creatine Kinase, MB Form; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Troponin T | 2009 |
Effects of rosuvastatin and atorvastatin on the apolipoprotein B/apolipoprotein A-1 ratio in patients with an acute coronary syndrome: The CENTAURUS trial design.
Topics: Acute Coronary Syndrome; Adolescent; Adult; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Double-Blind Method; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2008 |
[Non-ST-elevation acute coronary syndrome. Comparison of effects of atorvastatin and rosuvastatin on blood levels of lipids and markers of inflammation].
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Data Interpretation, Statistical; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Lipids; Lipoproteins; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Statistics, Nonparametric; Sulfonamides; Tumor Necrosis Factor-alpha | 2010 |
Comparison of the efficacy of rosuvastatin versus atorvastatin in reducing apolipoprotein B/apolipoprotein A-1 ratio in patients with acute coronary syndrome: results of the CENTAURUS study.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multicenter Studies as Topic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2010 |
12-month follow-up results of high dose rosuvastatin loading before percutaneous coronary intervention in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Female; Fluorobenzenes; Follow-Up Studies; Humans; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2011 |
Comparison of rosuvastatin and atorvastatin on clopidogrel response and lipidic and inflammatory parameters after coronary stenting for acute coronary syndrome: the prospective, randomized OSCAR study (optimal statin therapy with clopidogrel after coronar
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Clopidogrel; Combined Modality Therapy; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fluorobenzenes; Heptanoic Acids; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Stents; Sulfonamides; Ticlopidine | 2010 |
Rosuvastatin induces apoptosis in CD4(+)CD28 (null) T cells in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Apoptosis; CD4-Positive T-Lymphocytes; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2011 |
Intensive lipid-lowering therapy with rosuvastatin stabilizes lipid-rich coronary plaques. -Evaluation using dual-source computed tomography.-.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Coronary Angiography; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Male; Middle Aged; Plaque, Atherosclerotic; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Tomography, X-Ray Computed | 2011 |
Comparison of lipid-modifying efficacy of rosuvastatin versus atorvastatin in patients with acute coronary syndrome (from the LUNAR study).
Topics: Acute Coronary Syndrome; Adult; Aged; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiography; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Survival Rate; Treatment Outcome; United States; Young Adult | 2012 |
Effect of high-dose rosuvastatin loading before percutaneous coronary intervention in female patients with non-ST-segment elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; C-Reactive Protein; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-1; Interleukin-6; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Tumor Necrosis Factor-alpha | 2012 |
The effects and mechanisms of high loading dose rosuvastatin therapy before percutaneous coronary intervention in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Percutaneous Coronary Intervention; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2013 |
Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial).
Topics: Acute Coronary Syndrome; Aged; Apolipoproteins B; Cholesterol; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins; Male; Middle Aged; Prospective Studies; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2013 |
Effect of a single high loading dose of rosuvastatin on percutaneous coronary intervention for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; C-Reactive Protein; Chemokine CCL2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Interleukin-6; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Postoperative Complications; Preoperative Care; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2013 |
15 other study(ies) available for fluorobenzenes and Acute Coronary Syndrome
| Article | Year |
|---|---|
Prevention: Rosuvastatin can prevent contrast-induced AKI.
Topics: Acute Coronary Syndrome; Acute Kidney Injury; Angiography; Contrast Media; Coronary Angiography; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Humans; Male; Platelet Aggregation Inhibitors; Pyrimidines; Renal Insufficiency, Chronic; Sulfonamides | 2013 |
[The PRATO-ACS study].
Topics: Acute Coronary Syndrome; Acute Kidney Injury; Contrast Media; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides | 2013 |
Impact of high-dose statin pre-treatment and contrast-induced acute kidney injury on follow-up events in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Acute Kidney Injury; Atorvastatin; Contrast Media; Disease-Free Survival; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Percutaneous Coronary Intervention; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides | 2014 |
ACP Journal Club. Early high-dose rosuvastatin prevented contrast-induced acute kidney injury in non-ST-elevation ACS.
Topics: Acute Coronary Syndrome; Acute Kidney Injury; Contrast Media; Coronary Angiography; Female; Fluorobenzenes; Humans; Male; Platelet Aggregation Inhibitors; Pyrimidines; Sulfonamides | 2014 |
Takotsubo cardiomyopathy with involvement of delayed-onset rhabdomyolysis and acute kidney injury after rosuvastatin treatment.
Topics: Acute Coronary Syndrome; Acute Kidney Injury; Aged; Diagnosis, Differential; Electrocardiography; Fluorobenzenes; Heart Ventricles; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Rhabdomyolysis; Rosuvastatin Calcium; Sulfonamides; Takotsubo Cardiomyopathy; Treatment Outcome; Withholding Treatment | 2015 |
Persistent Excessive Electrocardiogram ST-segment Elevation in a Patient with a Takotsubo Syndrome: What Could be the Cause?
Topics: Acute Coronary Syndrome; Acute Kidney Injury; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Rhabdomyolysis; Sulfonamides; Takotsubo Cardiomyopathy | 2016 |
Statin, the black box.
Topics: Acute Coronary Syndrome; Atorvastatin; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2008 |
Pre-procedural use of statins for all patients undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Female; Fluorobenzenes; Humans; Male; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2011 |
Early intervention with rosuvastatin decreases the lipid components of the plaque in acute coronary syndrome: analysis using integrated backscatter IVUS (ELAN study).
Topics: Acute Coronary Syndrome; Aged; Cholesterol, LDL; Coronary Artery Disease; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Male; Middle Aged; Plaque, Atherosclerotic; Pyrimidines; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Ultrasonography, Interventional | 2011 |
Plaque-stabilizing statin therapy prior to percutaneous transluminal angioplasty and stenting.
Topics: Acute Coronary Syndrome; Coronary Angiography; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Plaque, Atherosclerotic; Pyrimidines; Sulfonamides; Tomography, X-Ray Computed | 2012 |
Current statin usage for patients with acute coronary syndrome undergoing percutaneous coronary intervention: multicenter survey in Korea.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Chi-Square Distribution; Drug Utilization; Drug Utilization Review; Evidence-Based Medicine; Female; Fluorobenzenes; Guideline Adherence; Health Care Surveys; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Percutaneous Coronary Intervention; Practice Guidelines as Topic; Practice Patterns, Physicians'; Prospective Studies; Pyrimidines; Pyrroles; Registries; Republic of Korea; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Time Factors | 2012 |
Rosuvastatin-induced high-density lipoprotein changes in patients who underwent percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Cardiovascular Diseases; Electrocardiography; Fluorobenzenes; Forecasting; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Lipoproteins, HDL; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Time Factors | 2012 |
[Inflammation, atherosclerosis, classic cardiovascular risk factors, biostatistics, clinical significance. Where are we?].
Topics: Acute Coronary Syndrome; Atherosclerosis; Biometry; Dyslipidemias; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypoglycemic Agents; Inflammation; Metformin; Oxidative Stress; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Tumor Necrosis Factor-alpha | 2007 |
Lipid levels in the post-acute coronary syndrome setting: destabilizing another myth?
Topics: Acute Coronary Syndrome; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Fluorobenzenes; Heptanoic Acids; Humans; Prognosis; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Time Factors | 2008 |
Lipid levels after acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adolescent; Adult; Aged; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Female; Fluorobenzenes; Heart Conduction System; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Prognosis; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides; Time Factors; Triglycerides | 2008 |